An ongoing dialogue on HIV/AIDS, infectious diseases,
June 20th, 2012
Abacavir Becomes the Latest Generic Antiretroviral Agent
Hot on the heels of generic nevirapine comes generic abacavir:
On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Ziagen Tablets, a product of VIIV Healthcare Company.
Note that this is for the separate 300 mg tablets, which are approved for twice-daily dosing, and not (yet) for the convenient coformulated once-daily abacavir/3TC tablet.
Nonetheless, it’s notable that a highly effective, well tolerated regimen — abacavir, 3TC, and efavirenz — could now be two-thirds generic, with the last third (efavirenz) probably becoming generic sometime soon.
Does that mean you’ll be switching your patients to generic abacavir once it appears in pharmacies? Let’s do a poll.
Categories: Health Care, HIV, Patient Care, Policy
Tags: 3tc, Abacavir, antiretroviral therapy, generic drugs
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “Abacavir Becomes the Latest Generic Antiretroviral Agent”
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- How Electronic Health Records Tyrannize Doctors — ID Doctors in Particular
- Five Reflections after Attending on General Medicine This Year
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- More on Munich and the 25th Annual International AIDS Conference
- How to Figure Out the Length of Antibiotic Therapy
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- Do Antivirals During Acute COVID-19 Lower Risk for Long COVID?
- How Well Does Hybrid Immunity Protect Immunocompromised Individuals Against COVID-19?
- Managing Prosthetic Joint Infections Caused by Candida Species
- High-Dose or Standard-Dose Influenza Vaccine: Which Is Better for Older Adults?
- Artificial Intelligence vs. ID Residents and Specialists: Who Tested Best?
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
how is abacavir’s mechanism of action?